# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# NCT05030064 (Continued)

# Exclusion Criteria

- Unspecified UC
- Travel abroad in past month
- History of alcoholism, drug abuse, or smelting
- Use of antibiotics and probiotic preparations within 1 month
- Bipolar disorder, persistent mood disorder, and mania
- Pregnancy and lactation
- Malignant tumors, gastrointestinal infection, IBS, bowel cancer and other gastrointestinal diseases
- History of gastrointestinal surgery
- Obesity, hypertension, diabetes, heart disease, stroke, and other serious chronic diseases (hereditary, metabolic, endocrine diseases)
- Other serious diseases (e.g. of the heart, brain, lung, liver, kidney)
- Infectious diseases: hepatitis B or C, HIV, syphilis (rapid recovery of positive plasma), EBV and CMV infection (immunoglobulin M positive)
- Abnormal liver function: AST or ALT > 2 × upper limit of normal
- Renal insufficiency: serum creatine > 1.5 × upper limit of normal or eGFR < 60 mL/minute
- Dyslipidemia: total cholesterol > 4.0 mmol/L, triglycerides > 2.0 mmol/L, low-density lipoprotein cholesterol > 2.5 mmol/L, high-density lipoprotein cholesterol < 1.0 mmol/L
- CRP > 8 mg/L
- Anticoagulation therapy
- Participation in other clinical trials at the time of enrollment
- Refusal to join group or other factors affecting compliance and participation

# Interventions

# Experimental arm

16 FMT capsules (each containing 200 mg of intestinal bacteria), once a week for 4 weeks

# Control arm

16 placebo capsules, once a week for 4 weeks

# Outcomes

# Primary outcome

PHQ-9 score at week 12

# Secondary outcomes

- Self-Rating Depression Scale score at week 12
- Hamilton Anxiety Scale score at week 12
- Hamilton Depression Scale score at week 12
- Hospital Anxiety and Depression Scale score at week 12
- Gastrointestinal Symptom Rating Scale score at week 12
- Modified Mayo score for UC at week 12
- IBDQ score at week 12
- WBC, CRP, ESR, procalcitonin, interleukin-6, intestinal flora at week 12

# Starting date

10 September 2021

# Contact information

Yanling Wei, Deputy Chief Physician, Third Military Medical University, Chongqing, China

Tel: 86-15310354666; email: lingzi016@126.com

# Notes

Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.